<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504946</url>
  </required_header>
  <id_info>
    <org_study_id>RNN-168-05-KE</org_study_id>
    <nct_id>NCT00504946</nct_id>
  </id_info>
  <brief_title>Pharmacological Modulations of Allergen-Specific Immunotherapy</brief_title>
  <official_title>The Effect of Glucocorticosteroid and Vitamin D3 Administration and Montelukast Treatment on Early Clinical and Immunological Effect of Allergen-Specific Immunotherapy in Asthmatic Children, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Universtity of Lodz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Universtity of Lodz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is mounting evidence that successful allergen immunotherapy (SIT) functions through the
      induction of different subset of Treg including Foxp3 positive cells, therefore additional
      strategies to enhance this property are highly attractive. Based on previous findings we
      assumed that combine allergen immunotherapy with non-specific treatments such as
      glucocorticosteroids and vitamin D3 as well as montelukast sodium treatment might enhanced
      allergen tolerance induction and improved clinical effectiveness of allergen-specific
      immunotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is mounting evidence that successful allergen immunotherapy (SIT) functions through the
      induction of different subset of Treg including Foxp3 positive cells, therefore additional
      strategies to enhance this property are highly attractive. Since corticosteroids directly
      induce the development of an IL-10-synthesizing regulatory T-cell population (Tr1) and this
      effect can be greatly increased with vitamin D3 treatment we , we assumed that combine
      allergen immunotherapy with non-specific treatments such as glucocorticosteroids and vitamin
      D3 as well as montelukast sodium treatment might enhanced allergen tolerance induction and
      improved clinical effectiveness of allergen-specific immunotherapy, therefore we conducted
      the stud comparing the effect of glucocorticosteroid, glucocorticosteroid with vitamin D3 or
      montelukast sodium on early immunological and clinical effect of allergen-specific
      immunotherapy in asthmatic children.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regulatory T cell (CD4+CD25+Foxp3 positive) induction measured in peripheral blood mononuclear cells</measure>
    <time_frame>First visit, second visit (after 3 months) and third visit (after 12 months of immunotherapy)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine (IL-10, TGF-beta1, IL-4, IL-5, IL-13) determination in supernatants from peripheral blood mononuclear cells culture.</measure>
    <time_frame>First visit, second visit (after 3 months) and third visit (after 12 months of immunotherapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diary card evaluation with asthma free days estimation, lung function measurement and analysis of reduction of the inhaled corticosteroids dose</measure>
    <time_frame>Visit first and third visit (after 12 months of immunotherapy)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone, lactose</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
20mg prednisone+ 0.3mg lactose</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone, colecalciferol, lactose</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
20mg prednisone + 1000j colecalciferol + 0.3mg lactose</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactose</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
0.3mg lactose</description>
    <arm_group_label>III</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children &gt; 14 years old received 10mg oral tablet once daily at bedtime</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactose</intervention_name>
    <description>Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Miflonide</other_name>
    <other_name>Pulmicort</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allergic asthma with regular symptoms requiring long-term treatment with inhaled
             corticosteroids

          -  disease duration of at least 2 years

          -  sensitisation only to house dust mites

          -  resting FEV1 of more or equal 70%

        Exclusion Criteria:

          -  sensitization to allergens other than house dust mites

          -  discontinuation of SIT from any reasons

          -  need of a daily dose below 200 or above 800 mcg of budesonide or equivalent

          -  other chronic disease including vitamin D3 deficiency and/or resistance which could
             influence the results of the study or the patient's ability to participate in the
             study as judged by the investigator

          -  medications that resulted in patient exclusion included: inhaled long acting
             β2-agonist, leukotriene modifiers, β-blockers (eye drops included) or oral
             corticosteroids within 6 month before the pre-study visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paweł Majak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iwona Stelmach, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics and Allergy, Medical University of Lodz, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>April 8, 2008</last_update_submitted>
  <last_update_submitted_qc>April 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Universtity of Lodz</name_title>
    <organization>Department of Pediatrics and Allergy</organization>
  </responsible_party>
  <keyword>allergen immunotherapy premedication</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

